newsfilter
← Latest News
Business Wire·

Holocene Advisors Believes Merck's Proposed Offer of $180 Per Share for Acceleron Significantly Undervalues Company

Long-term Holder Does Not Intend to Tender Shares into Merck's Offer Holocene Advisors, LP ("Holocene"), a fundamental investment management firm and significant shareholder of Acceleron Pharma Inc. (NASDAQ:XLRN) ("Acceleron" or the "Company"), toda